Distinct genotypic and phenotypic forms of methylmalonyl CoA mutase (MCM) apoenzyme deficiency can be delineated by biochemical analysis of mutant fibroblasts. One form, designated mut-, expresses a phenotype in which residual enzyme activity is evident in cultured cells exposed to high concentrations of hydroxycobalamin. We describe cloning of an MCM cDNA from cells exhibiting a mut-phenotype and characterization of the mutant gene product overexpressed in primary mut' human fibroblasts and Saccharomyces cerevisiae. Three novel base changes were observed. Recombinant clones containing one of these base changes (G717V) express four characteristics of the mut-phenotype: failure to constitute 14Cqpropionate incorporation activity in fibroblasts assayed under basal cell culture conditions, constitution of 1[4Cjpropionate incorporation activity in fibroblasts stimulated with 0.1-1.0 ,g/ml hydroxycobalamin, interallelic complementation with alleles bearing an R93H mutation, and an apparent K. (adenosylcobalamin) 1,000-fold higher than normal. These results demonstrate that the G717V mutation produces the mut-phenotype and localizes determinants for adenosylcobalamin binding near the carboxyl terminus of MCM. (J. Clin. Invest. 1992. 89:385-391.) 
. The MCM holoenzyme is a homodimer that contains 1 mol of an adenosylcobalamin cofactor for each mole ofsubunit (2) . Distinct genotypic forms of MMA are caused by defects in the MCM apoenzyme (designated mut MMA; McKusick number 251000; reference 3) or defects in enzymes required for providing the adenosylcobala-min cofactor (designated cbl MMA; McKusick numbers 251100 and 251110; reference 3). Two distinct phenotypic forms of mut MMA can be delineated by biochemical analysis of fibroblasts from patients with MMA: mulP, in which fibroblasts exhibit no ['4C]propionate incorporation under any conditions or detectable MCM apoenzyme activity in vitro, and mut-, in which fibroblasts exhibit ['4C]propionate incorporation when stimulated by high concentrations of hydroxycobalamin (4) (5) (6) (7) . This biochemical variation is thought to underlie the varied clinical expressions ofMCM deficiency, which range from fulminant neonatal acidosis, multiorgan failure, and death (8) to benign, persistent MMA without any corresponding clinical or developmental abnormalities (9) .
Additional classes of mut MMA have recently been delineated by somatic cell complementation studies with mut°W G1 130 fibroblasts (10 We have reported cloning of the normal human MCM cDNA, which comprises 2,798 bases and encodes a propeptide of 750 amino acids (83,007 D) with a 32-amino acid mitochondrial targeting sequence and a 718-amino acid mature apoenzyme (1 1, 12) . DNA-mediated gene transfer ofthis clone into primary mulP fibroblasts restores [14C] propionate incorporation to normal levels during the transient phase of recombinant gene expression after electroporation (13) , confirming that defects at this gene locus are responsible for the mut genotype. The recombinant MCM apoenzyme has been expressed at high levels in Saccharomyces cerevisiae for biochemical analysis and has been shown to exhibit kinetic parameters indistinguishable from the native enzyme (Andrews, E., R. Jansen, A. M. Crane, M. F. Wilkemeyer, D. McDonnell, and F. D. Ledley, unpublished data). Of particular relevance to the present experiments is the fact that S. cerevisiae does not have endogenous MCM (14) and does not produce adenosylcobalamin, so that the recombinant MCM produced in this organism is entirely apoenzyme.
Several mutations have been identified in human MCM (10, 15, 16), including two nonsense mutations (W1O5R and A378E) that give rise to a classic mut°phenotype (16) and a mutation (R93H) that exhibits interallelic complementation (10) with mut fibroblasts. We describe here the cloning, sequencing, and expression of an MCM mutation expressing the mut-phenotype and the characterization of the activity of the recombinant gene product expressed in fibroblasts and S. cerevisiae.
GM 1673 fibroblasts were obtained from the National Institute ofGeneral Medical Sciences (Bethesda, MD) Mutant Cell Repository and were previously shown to express a mut' phenotype with low levels of MCM mRNA (7) . MAS and WG1 130 are mut' cell lines, the mutations of which have been described previously (10, 16) .
Cloning and sequencing ofMCM cDNA. Total RNA was prepared from confluent fibroblasts, and cDNA was synthesized and amplified by polymerase chain reaction (PCR; Fig. 1 ) as described previously (16) . First-strand cDNA was generated from oligonucleotide 33 in the 3' untranslated region ofthe cDNA and used as a template for two PCR reactions between oligonucleotides 53 and 28 and between oligonucleotides 23 and 21. The products of the 5' reaction were cloned into the ClaI/KpnI sites of pGEM7zft+) using the ClaI site within oligonucleotide 53 and the internal KpnI site at base 720. The products of the 3' reaction were cloned into the KpnI/BamHI sites of pGEM7zf(+) using the internal KpnI and BclI sites. Double-stranded dideoxy sequencing was performed using the T7-(Q501 1, Promega Corp., Madison, WI), SP6-(Q512 1, Promega), or MCM-specific primers (Fig. 1) . Clonal isolates were sequenced and compared with the sequence from a pool of 15 independent clones to confirm the authenticity of sequence variations. Oligonucleotide sequences are in reference 16.
DNA-mediated gene transfer and assay of["C]propionate incorporation in fibroblasts. An expression vector was constructed using the normal human MCM cDNA (pCMV-hMCM) in the plasmid pNAssCMV (17, 18) , the cytomegalovirus immediate early promoter, the SV40 late viral protein splice donor and acceptor signals, and the SV40 polyadenylation sequences (Fig. 3 A, clone F) . Mutant clones were constructed by substituting fragments from the PCR-generated cDNA clones into the normal vector (Fig. 3 A) . A BamHI/NsiI fragment containing H532R (base 1,671) was replaced in a subclone containing the 5' end of the normal MCM gene (Fig. 3 A, clone 1) . A NsiI/EcoRI fragment containing V67 11 (base 2,087) and G717V (base 2,226) was combined with fragments from the normal hMCM expression vector (Fig. 3 A, incorporation in the presence of 1.0 ug/ml hydroxycobalamin. Significant propionate incorporation is determined from the mean and standard deviation compared with GM 1673 controls.
Expression and enzyme assays in S. cerevisiae. The vector pYEPVhMCM for expression of human MCM in S. cerevisiae will be described elsewhere (Andrews, E., R. Jansen, A. M. Crane, M. F. Wilkemeyer, D. McDonnell, and F. R. Ledley, unpublished data). This clone contains the human MCM open reading frame with truncated 5' and 3' untranslated regions, the CUPlp promoter, 2s origin of replication, and TRP-l gene for tryptophan selection (22) (Fig. S A) . Sequence fragments containing all three sequence variations or only G717V were substituted into this vector on a KpnI/EcoRI segment by three-part ligation of the mutant KpnI/EcoRI fragment with EcoRI/ClaI and KpnI/ClaI fragments from the normal clone. The clones were introduced into the proteinase-deficient S. cerevisiae strain BJ3505 (TrplI, Ura3Y), and expression ofthe recombinant gene was induced with 100 MM CuS04 when cultures reached an OD6w of 0.5. The cells were harvested 4 h after induction by centrifugation; lysed using GlassperlenTM (B. Braun Melsungen, Melsungen, Germany) (0.45-0.5 mm) in 28 mM NaPO4, pH 7.0, 5 mM EDTA; and cleared of particulate matter by centrifugation.
MCM activity was measured in vitro using the potassium permanganate/perchloric acid method (23) (24) (25) . Each reaction contained 50-200Mgg crude extract, 100 mM Tris-PO4, pH 7.5, 0.5-2 mM D/L-methylmalonyl CoA (Sigma Chemical Co., St. Louis, MO), 160,000 dpm D/L-['4C]methylmalonyl CoA (56 mCi/mmol, Amersham Corp., Ar- lington Heights, IL), and 0-1.0 mM adenosylcobalamin in a volume of 300,Ml. The reaction was incubated in the dark for 20 min at 30°C and stopped by adding 100 Ml 2 M perchloric acid and boiling. The total protein content was determined using a protein assay (BioRad Laboratories). Each Identification ofmutations in DS79. Three differences were identified between the sequence of DS79 and the consensus sequence: H532R (a -g, base 1,671), V6711 (g --a, base 2,087), and G717V (g t, base 2,226) (Fig. 2) . All three novel sequences were uniformly present in a mixture of 15 cDNA clones, suggesting that these sequences were not PCR artifacts. Thus, this patient is homozygous for all three novel sequences or is a compound heterozygote in which the heterologous allele is not represented in the cDNA clones (15) .
To confirm that these sequence variations were responsible for the mur phenotype, an expression vector that contained all three changes was constructed (Fig. 3 A, (Fig. 3 B, lane A) . This stimulation is quantitatively similar to the ['4C]propionate incorporation observed in the parental DS79 cells without electroporation (Fig. 3 C, BLANK ) or after electroporation with the vector alone ( Fig. 3 C, CMV ). These data demonstrate that the MCM cDNA from the DS79 fibroblasts expressed the phenotype of the parental cells.
Expression constructs were made with different permutations of the three potential mutations to determine which amino acid change was responsible for the pathological phenotype. Clones containing only H532R (Fig. 3 A, clone B) or only V67 11 (Fig. 3 A, clone D) induced ['4C]propionate incorporation (Fig. 3 B, lanes B and D) equivalent to that of a normal MCM clone (Fig. 3 B, lane F) . Clones containing both V67 I1 and G717V (Fig. 3 A, clone C) or only G717V (Fig. 3 A, (Fig. 3 B, lanes C and E) . Thus, G717V alone was responsible for the impaired MCM activity in DS79 cDNA clones.
Interallelic complementation between G717V and R93H mutations. To test whether the G717V mutation exhibited the complete phenotype ofthe parental DS79 fibroblasts, we investigated whether clones with G717V would complement the R93H mutation (10). It (Fig. 4 A) or into DS79 (Fig. 4 B) (Fig. 4 B) . These experiments demonstrate selective interallelic complementation between the G717V and R93H mutations.
Characteristics ofthe mutant geneproduct. Segments ofthe mutant cDNA bearing all three novel sequences or the G717V mutation alone were substituted for normal sequences in the expression vector YEPV-MCM (Fig. 5 A) S. cerevisiae. No MCM enzyme activity was detected in extracts containing the mutant enzyme in the presence of concentrations of adenosylcobalamin < 10 ,uM, which stimulated maximal activity of the normal enzyme. MCM (Fig. 3 A, which is not conservative because of the critical role glycine residues play in the secondary structure, stabilizing (-turns and disrupting both regular a-helical and (3-sheet structures. ChouFasman predictions ofsecondary structure (28, 29) for the normal and mutant sequences in this region suggest either that the absence of the helix terminating glycine could enable an adjacent a-helix to extend further toward the carboxy terminus, or that valine in this position could initiate (3-sheet formation that would not be predicted for the normal protein (Fig. 6 ).
Homologous MCM genes have been cloned from mouse and from the prokaryote Propionibacterium shermanii. The murine enzyme exhibits 94% amino acid sequence identity and similar kinetics as human (26) . P. shermanii MCM is a heterodimer of homologous a (MUTB gene) and (3 (MUTA gene) subunits (30, 31) . There is a 59% identity between human MCM and the P. shermanii MUTB gene and a 22% identity between human MCM and the MUTA gene (32) . The glycine residue at position 717 is conserved in human, murine, and P. shermanii MUTB sequences but not in MUTA (Fig. 6 ). There is, however, little overall sequence preservation between the eukaryotic and prokaryotic enzymes in the regions immediately surrounding this glycine. There is similarity in flanking regions that could fold together to constitute homologous cobalamin-binding determinants. This pattern ofhomology predicts that the effect of the G7 1 7V mutation may be to disrupt the tertiary assembly of these determinants by introducing additional rotation at the end ofa segment of a-helix or folding this region deeper into the hydrophobic core of the protein.
The position of this mutation and the pattern of homology between the eukaryotic and prokaryotic enzymes are interesting, considering the interallelic complementation observed between G717V and R93H. It has been proposed that this complementation may result from constitution of a single asymmetrical catalytic center composed ofcobalamin-binding determinants from clones bearing the R93H mutation with discrete catalytic functions remaining on mut alleles (10). This is consistent with evidence that the normal enzyme binds 2 mol of adenosylcobalamin/homodimer (2) and with a model in which the catalytic core is composed of two symmetrical catalytic centers constituted in trans from determinants on opposite subunits. It is interesting that there is no apparent homology between MUTB and MUTA in the regions surrounding this presumed cobalamin-binding site, given the observation that P. shermanii MCM binds only 1 mol adenosylcobalamin/ heterodimer (Leadlay, P. F., personal communication). A more detailed picture of structure function determinants will arise from knowledge ofthe tertiary structure ofMCM (33) and additional characterization of natural or site-directed mutants of the eukaryotic or prokaryotic proteins.
